Alzheimer’s Disease International, Guerchet, M., Prince, M. & Prina, M. Numbers of People with Dementia Worldwide: An Update to the Estimates in the World Alzheimer Report 2015 (Alzheimer’s Disease International, 2020).

Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 16, 391–460 (2020).

Article  Google Scholar 

Jack, C. R. Jr et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Barnes, D. E. & Yaffe, K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 10, 819–828 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Livingston, G. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396, 413–446 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312–339 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Vandenbroucke, J. P. Observational research, randomised trials, and two views of medical science. PLoS Med. 5, e67 (2008).

Article  PubMed  PubMed Central  Google Scholar 

Frieden, T. R. Evidence for health decision making-Beyond randomized, controlled trials. N. Engl. J. Med. 377, 465–475 (2017).

Article  PubMed  Google Scholar 

Stoiljkovic, M., Horvath, T. L. & Hajós, M. Therapy for Alzheimer’s disease: missing targets and functional markers? Ageing Res. Rev. 68, 101318 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Freedman, B. Equipoise and the ethics of clinical research. N. Engl. J. Med. 317, 141–145 (1987).

Article  PubMed  Google Scholar 

Fewell, Z., Davey Smith, G. & Sterne, J. A. C. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am. J. Epidemiol. 166, 646–655 (2007).

Article  PubMed  Google Scholar 

Hernán, M. A. & Robins, J. M. Estimating causal effects from epidemiological data. J. Epidemiol. Community Health 60, 578–586 (2006).

Article  PubMed  PubMed Central  Google Scholar 

Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. Int. J. Epidemiol. 45, 1866–1886 (2016).

PubMed  Google Scholar 

Balshem, H. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 64, 401–406 (2011).

Article  PubMed  Google Scholar 

Lash, T. L. et al. Modern Epidemiology (Wolters Kluwer, 2021).

Koepsell, T. D. Epidemiologic Methods: Studying the Occurrence of Illness (Oxford University Press, 2014).

Dougherty, D. & Conway, P. H. The “3T’s” road map to transform US health care: the “How” of high-quality care. JAMA 299, 2319–2321 (2008).

Article  PubMed  Google Scholar 

Trochim, W., Kane, C., Graham, M. J. & Pincus, H. A. Evaluating translational research: a process marker model. Clin. Transl. Sci. 4, 153–162 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Sperling, R. A., Jack, C. R. & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm33 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Schneider, J. A., Arvanitakis, Z., Bang, W. & Bennett, D. A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197–2204 (2007).

Article  PubMed  Google Scholar 

Nelson, P. T. et al. ‘New Old Pathologies’: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). J. Neuropathol. Exp. Neurol. 75, 482–498 (2016).

Article  PubMed  PubMed Central  Google Scholar 

McAleese, K. E. et al. Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimers Dement. J. Alzheimers Assoc. 17, 1121–1133 (2021).

Article  Google Scholar 

Vemuri, P. et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 138, 761–771 (2015).

Article  PubMed  PubMed Central  Google Scholar 

White, L. R. et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology 86, 1000–1008 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Brenowitz, W. D. et al. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement. 13, 654–662 (2017).

Article  PubMed  Google Scholar 

Beach, T. G., Monsell, S. E., Phillips, L. E. & Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J. Neuropathol. Exp. Neurol. 71, 266–273 (2012).

Article  PubMed  Google Scholar 

Ackley, S. F. et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ 372, n156 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Alexander, G. C. et al. Revisiting FDA approval of aducanumab. N. Engl. J. Med. 385, 769–771 (2021).

Article  PubMed  Google Scholar 

Anderson, T. S., Ayanian, J. Z., Souza, J. & Landon, B. E. Representativeness of participants eligible to be enrolled in Clinical Trials of Aducanumab for Alzheimer disease compared with Medicare beneficiaries with Alzheimer Disease and Mild Cognitive Impairment. JAMA 326, 1627–1629 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Berchtold, N. C. & Cotman, C. W. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol. Aging 19, 173–189 (1998).

Article  PubMed  Google Scholar 

Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357 (1997).

Article  PubMed  Google Scholar 

Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989–997 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51, 414–430 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Chartier-Harlin, M. C. et al. Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353, 844–846 (1991).

Article  PubMed  Google Scholar 

Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923 (1993).

Article  PubMed  Google Scholar 

Hamilton, R. L. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10, 378–384 (2000).

Article  PubMed  Google Scholar 

Mirra, S. S. et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41, 479–486 (1991).

Article  PubMed  Google Scholar 

Newell, K. L., Hyman, B. T., Growdon, J. H. & Hedley-Whyte, E. T. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J. Neuropathol. 58, 1147–1155 (1999).

Article  Google Scholar 

McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65, 1863–1872 (2005).

Article  PubMed  Google Scholar 

Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992).

Article  PubMed  Google Scholar 

Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Pascoal, T. A. et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res. Ther. 10, 74 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Clark, C. M. et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 305, 275–283 (2011).